Navigation Links
AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
Date:12/1/2011

ward-looking statements in this news release include statements regarding the Company's milestones, future filings and trials, markets, mechanisms of action, licensing agreements and equity investment as well as the development of applications for AtheroNova's technology. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in AtheroNova's filings with the United States Securities and Exchange Commission. AtheroNova undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE AtheroNova Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AtheroNova Rodman & Renshaw Presentation Now Online at www.AtheroNova.com
2. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
3. DFB Pharmaceuticals Appoints Maxwell Lea to Vice President Business Development and Corporate Finance
4. New Promega Maxwell 16 LEV Blood DNA Kit Surpasses Concentration Standards in Less Time
5. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
6. Yongye Biotechnology International Retains CCG Investor Relations
7. ThirdBiotech Announces Kemeta as Newest Sponsor
8. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
9. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
10. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
11. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... CHANDLER, Ariz. , July 1, 2015 ... announced it has earned three Gold, three Silver, and ... Business Awards gala held in Chicago ... recognized as the premier business awards program in the ... and recognizes our company,s strength in developing leaders, cultivating ...
(Date:7/1/2015)... ... , ... Apex Therapeutics announced today that company CEO, David Broecker provided a ... The presentation took place on Tuesday, June 16 and provided an update on the ... the treatment of pancreatic cancer. A copy of the company overview can be ...
(Date:6/30/2015)... -- R-Japan Co.,Ltd. obtained the license of cell processing facility ... the Ministry of Health, Labour and Welfare Kinki Bureau of ... The fact that R- Japan received the ... and Medical Devices Agency (PMDA) on May 18, 2015 two ... cell manufacturing service to medical institutions. As of November 25, ...
(Date:6/30/2015)... Santa Clara CA (PRWEB) , ... June 30, ... ... force microscopy (AFM) is hosting a webinar to provide advanced scientific research into ... material science, bio science and energy. Touted as 'the wonder material of ...
Breaking Biology Technology:Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4
... BioMarin Pharmaceutical,Inc. (Nasdaq: BMRN ) announced ... for the Riquent(R) Phase 3 ASPEN trial, the ... of the trial is,futile. BioMarin and partner ... unblind the data and evaluate all of the ...
... announced a vibrant new addition today to their dynamic ... Maine, was unanimously elected by the Board to fill ... successful biotechnology professional with 20 years of experience in ... career accomplishments that include establishing and launching successful business ...
... IdeasProject.com, Nokia,s new website, which provides innovative ways to interact with ... , ... San Francisco, CA (PRWEB) February 12, 2009 ... of genetic testing service 23andme, says that as we further our ...
Cached Biology Technology:Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile 2Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile 3SenesTech, Inc. Appoints Susan Airhart to Board of Directors 2Famed IT Investor and Director of 23andme Esther Dyson Identifies on IdeasProject.com Genetic Information as an Extremely Disruptive Force 2Famed IT Investor and Director of 23andme Esther Dyson Identifies on IdeasProject.com Genetic Information as an Extremely Disruptive Force 3
(Date:6/16/2015)... , June 16, 2015 /CNW Telbec/ - ... partnership centralized around the incorporation of handyem,s HPC-150 ... diagnostic laboratory, the Mo-POD™. This unprecedented model of ... International Conference at the Pennsylvania ... from June 15 th to 18 th ...
(Date:6/15/2015)... , June 15, 2015 A ... from Telstra reveals the majority of US consumers using mobile ... via biometrics, such as fingerprint and voiceprint, instead of having ... According to Telstra,s " Mobile Identity   -   ... report, with smartphones now the primary channel used by ...
(Date:6/9/2015)... MINNETONKA, Minn. , June 9, 2015   ... that supports the entire spectrum of clinical research, will ... eClinical technology platform at the 2015 Drug Information ... on June 15-17.  These presentations will include ... be rolled out in the upcoming iMedNet ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3
... ARBOR, Mich.---Scientists at the University of Michigan have ... safe for regenerating tooth-supporting gum tissue---a discovery that ... gene therapy research and tissue engineering. ... but safety is a major hurdle, said William ...
... touted as the next best source for fueling the ... in creating biofuels ,from algae is that when you ... ,organisms, dramatically raising production costs. Now researchers at the ... University have ,developed groundbreaking "nanofarming" technology that safely harvests ...
... top technological universities have come together to form ... brings together these leading engineering-based universities in the ... address global societal issues is through the joint ... top class research in science and technology. ...
Cached Biology News:Gene therapy appears safe to regenerate gum tissue 2Nanofarming technology harvest biofuel oils without harming algae 2Global alliance of leading technological universities to address global societal issues 2
iEMS Thermal Microplate Holder...
...
Improve inventory management with stainless steel red cell canisters; ensure product safety with CO2 or LN2 backup systems. A complete solution for your blood banking needs....
... oligonucleotides: PTOs are internucleotide modifications, ... backbone is replaced by a sulphur atom. ... degradation. PTOs are available as ... Oligonucleotides with thio-caps ...
Biology Products: